By evaluating the IFN-γ production, we could observe that IgG from ACs, HAM, and ATLL patients could reduce the frequency of IFN-γ-producing B cells compared to mock, IVIg, and HCs controls (Figure 4B and Supplementary Figure S5). This evidence concerns the gene IFNG and adult T-cell leukemia/lymphoma.